VIVUS, Inc. Files Definitive Proxy Materials With SEC

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MOUNTAIN VIEW, Calif., June 5, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a pharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today announced that it has filed its definitive proxy materials in connection with the Company’s 2013 Annual Meeting of Stockholders, to be held on July 15, 2013, with the Securities and Exchange Commission (“SEC”). VIVUS stockholders of record at the close of business on May 31, 2013 are entitled to vote at the 2013 Annual Meeting.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC